Published in Am J Ophthalmol on February 01, 2012
Endophthalmitis. Clin Microbiol Infect (2013) 1.79
Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond) (2013) 1.67
[Reliability and safety of intravitreal Ozurdex injections. The ZERO study]. Ophthalmologe (2014) 1.18
Endophthalmitis caused by streptococcal species: clinical settings, microbiology, management, and outcomes. Am J Ophthalmol (2014) 1.03
Factors affecting visual outcome of myopic choroidal neovascularization treated with verteporfin photodynamic therapy. Int J Ophthalmol (2013) 1.00
Outbreak of Serratia marcescens bloodstream infections in patients receiving parenteral nutrition prepared by a compounding pharmacy. Clin Infect Dis (2014) 0.98
Streptococcus endophthalmitis outbreak after intravitreal injection of bevacizumab: one-year outcomes and investigative results. Ophthalmology (2013) 0.96
Description of outbreaks of health-care-associated infections related to compounding pharmacies, 2000-12. Am J Health Syst Pharm (2013) 0.90
Quality of bevacizumab compounded for intravitreal administration. Eye (Lond) (2013) 0.87
Global reported endophthalmitis risk following intravitreal injections of anti-VEGF: a literature review and analysis. Clin Ophthalmol (2015) 0.83
Balancing antimicrobial efficacy and toxicity of currently available topical ophthalmic preservatives. Saudi J Ophthalmol (2014) 0.83
Endophthalmitis following intravitreal anti-vascular endothelial growth factor (VEGF) injection: a comprehensive review. Int J Retina Vitreous (2015) 0.82
Growth of Scytalidium sp. in a counterfeit bevacizumab bottle. Indian J Ophthalmol (2013) 0.80
The results of pars plana vitrectomy and silicone oil tamponade for endophthalmitis after intravitreal injections. Int Ophthalmol (2013) 0.79
Endophthalmitis outbreak associated with repackaged bevacizumab. Emerg Infect Dis (2015) 0.77
[Bacterial contamination of needles after intravitreal injection in Paraguay]. Ophthalmologe (2012) 0.76
Streptococcus mitis/oralis endophthalmitis management without phakic intraocular lens removal in patient with iris-fixated phakic intraocular lens implantation. BMC Ophthalmol (2014) 0.75
Association of Compounded Bevacizumab With Postinjection Endophthalmitis. JAMA Ophthalmol (2015) 0.75
Intravitreal administration of bevacizumab: pros and cons. Daru (2015) 0.75
An outbreak of Ralstonia pickettii endophthalmitis following intravitreal methotrexate injection. Clin Ophthalmol (2015) 0.75
U.S. Compounding Pharmacy-Related Outbreaks, 2001-2013: Public Health and Patient Safety Lessons Learned. J Patient Saf (2015) 0.75
Incidence of Endophthalmitis after Intravitreal Bevacizumab using Aliquots Prepared On-site in 2 Operating Rooms in Kuwait. Middle East Afr J Ophthalmol (2016) 0.75
Avastin and Lucentis: what do patients know? A prospective questionnaire survey. JRSM Short Rep (2013) 0.75
Storage stability of bevacizumab in polycarbonate and polypropylene syringes. Eye (Lond) (2015) 0.75
Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med (2011) 19.42
Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina (2006) 3.48
Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file. Am J Ophthalmol (2011) 3.24
Endophthalmitis after intravitreal vascular [corrected] endothelial growth factor antagonists: a six-year experience at a university referral center. Retina (2011) 2.97
Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina (2011) 2.15
Ranibizumab for age-related macular degeneration. N Engl J Med (2011) 2.03
Endophthalmitis caused by Streptococcus pneumoniae. Am J Ophthalmol (2004) 1.91
Counterfeit bevacizumab and endophthalmitis. N Engl J Med (2011) 1.18
Persistent endophthalmitis after intravitreal antimicrobial therapy. Ophthalmology (1995) 1.12
Serratia marcescens endophthalmitis associated with intravitreal injections of bevacizumab. Eye (Lond) (2009) 1.11
Microbial contamination of syringes during preparation: the direct influence of environmental cleanliness and risk manipulations on end-product quality. Am J Health Syst Pharm (2009) 0.98
Endophthalmitis after intravitreal injection: prevention and management. Retina (2011) 0.89
An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol (2007) 8.12
A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol (2009) 5.41
Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina (2006) 3.48
Endophthalmitis associated with intravitreal injections: office-based setting and operating room setting. Retina (2014) 3.41
Evolving guidelines for intravitreous injections. Retina (2004) 3.39
Endophthalmitis isolates and antibiotic sensitivities: a 6-year review of culture-proven cases. Am J Ophthalmol (2004) 2.98
Endophthalmitis after intravitreal vascular [corrected] endothelial growth factor antagonists: a six-year experience at a university referral center. Retina (2011) 2.97
Endophthalmitis isolates and antibiotic susceptibilities: a 10-year review of culture-proven cases. Am J Ophthalmol (2013) 2.90
Acute-onset endophthalmitis after cataract surgery (2000-2004): incidence, clinical settings, and visual acuity outcomes after treatment. Am J Ophthalmol (2005) 2.66
Infectious keratitis progressing to endophthalmitis: a 15-year study of microbiology, associated factors, and clinical outcomes. Ophthalmology (2012) 2.41
Ocular flora and their antibiotic resistance patterns in the midwest: a prospective study of patients undergoing cataract surgery. Am J Ophthalmol (2012) 2.18
Retained lens fragments after cataract surgery: outcomes of same-day versus later pars plana vitrectomy. Am J Ophthalmol (2013) 2.13
Pars plana vitrectomy for vitreous floaters: is there such a thing as minimally invasive vitreoretinal surgery? Retina (2014) 2.11
The diagnostic utility of anterior chamber paracentesis with polymerase chain reaction in anterior uveitis. Am J Ophthalmol (2013) 2.08
Insurgence of Fusarium keratitis associated with contact lens wear. Arch Ophthalmol (2006) 2.05
In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens. Am J Ophthalmol (2004) 2.00
Visual and anatomical outcomes of macular epiretinal membrane peeling after previous rhegmatogenous retinal detachment repair. Retina (2015) 1.98
Endogenous fungal endophthalmitis: causative organisms, management strategies, and visual acuity outcomes. Am J Ophthalmol (2011) 1.92
Pathogenesis of macular holes and therapeutic implications. Am J Ophthalmol (2004) 1.91
Endophthalmitis caused by Streptococcus pneumoniae. Am J Ophthalmol (2004) 1.91
Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina (2002) 1.86
Delayed- versus acute-onset endophthalmitis after cataract surgery. Am J Ophthalmol (2011) 1.83
Nosocomial acute-onset postoperative endophthalmitis at a university teaching hospital (2002-2009). Am J Ophthalmol (2010) 1.82
Acute-onset endophthalmitis after clear corneal cataract surgery (1996-2005). Clinical features, causative organisms, and visual acuity outcomes. Ophthalmology (2007) 1.79
Pars plana vitrectomy with internal limiting membrane peeling for diabetic macular edema. Retina (2008) 1.75
Culture-proven endogenous endophthalmitis: clinical features and visual acuity outcomes. Am J Ophthalmol (2004) 1.74
Fungal keratitis associated with non-therapeutic soft contact lenses. Am J Ophthalmol (2006) 1.67
ENDOPHTHALMITIS CAUSED BY PSEUDOMONAS AERUGINOSA: Clinical Features, Antibiotic Susceptibilities, and Treatment Outcomes. Retina (2015) 1.58
Endophthalmitis after 25-gauge and 20-gauge pars plana vitrectomy: incidence and outcomes. Retina (2008) 1.57
Photoreceptor inner/outer segment defect imaging by spectral domain OCT and visual prognosis after macular hole surgery. Invest Ophthalmol Vis Sci (2009) 1.54
Exogenous fungal endophthalmitis: microbiology and clinical outcomes. Ophthalmology (2008) 1.51
Anterior chamber and vitreous concordance in endophthalmitis: implications for prophylaxis. Arch Ophthalmol (2010) 1.50
Diversity of bacteria at healthy human conjunctiva. Invest Ophthalmol Vis Sci (2011) 1.50
Staphylococcus aureus endophthalmitis: antibiotic susceptibilities, methicillin resistance, and clinical outcomes. Am J Ophthalmol (2009) 1.48
Antimicrobial resistance profiles of ocular and nasal flora in patients undergoing intravitreal injections. Am J Ophthalmol (2011) 1.44
Endophthalmitis caused by Mycobacterium chelonae: selection of antibiotics and outcomes of treatment. Arch Ophthalmol (2003) 1.44
Reducing the risk of endophthalmitis following intravitreal injections. Retina (2007) 1.39
Spectral-domain optical coherence tomography appearance of preretinal aggregation of intravitreal antibiotics. Retina (2010) 1.38
Endophthalmitis caused by Pseudomonas aeruginosa. Ophthalmology (2003) 1.36
Incidence of endophthalmitis after 20-gauge vs 23-gauge vs 25-gauge pars plana vitrectomy. Graefes Arch Clin Exp Ophthalmol (2010) 1.33
Sympathetic ophthalmia: incidence of ocular complications and vision loss in the sympathizing eye. Am J Ophthalmol (2009) 1.33
Open globe injuries with positive intraocular cultures: factors influencing final visual acuity outcomes. Ophthalmology (2003) 1.29
Pathogenesis and outcome of Paecilomyces keratitis. Am J Ophthalmol (2009) 1.28
Advanced fusarium keratitis progressing to endophthalmitis. Cornea (2003) 1.28
Update on bacterial conjunctivitis in South Florida. Ophthalmology (2007) 1.27
Polymerase chain reaction analysis of aqueous and vitreous specimens in the diagnosis of posterior segment infectious uveitis. Am J Ophthalmol (2008) 1.24
Endophthalmitis caused by enterococcus faecalis: antibiotic selection and treatment outcomes. Ophthalmology (2003) 1.21
Colletotrichum keratitis. Am J Ophthalmol (2002) 1.21
Delayed-onset bleb-associated endophthalmitis (1996-2008): causative organisms and visual acuity outcomes. Retina (2011) 1.20
Update on retinal detachment surgery. Curr Opin Ophthalmol (2013) 1.19
Delayed-onset bleb-associated endophthalmitis: clinical features and visual acuity outcomes. Ophthalmology (2002) 1.18
Anti-VEGF Treatment Strategies for Wet AMD. J Ophthalmol (2012) 1.17
Epidemiology and visual outcomes in patients with infectious scleritis. Cornea (2013) 1.15
Intravitreal injection technique and monitoring: updated guidelines of an expert panel. Retina (2014) 1.15
Intravitreal injection analysis at the Bascom Palmer Eye Institute: evaluation of clinical indications for the treatment and incidence rates of endophthalmitis. Clin Ophthalmol (2010) 1.14
Endophthalmitis after pars plana vitrectomy: Incidence, causative organisms, and visual acuity outcomes. Am J Ophthalmol (2004) 1.12
Persistent outer retinal defect after successful macular hole repair. Am J Ophthalmol (2005) 1.12
In vitro fluoroquinolone resistance in staphylococcal endophthalmitis isolates. Arch Ophthalmol (2006) 1.11
Outcomes of surgery for retinal detachment associated with proliferative vitreoretinopathy using perfluoro-n-octane: a multicenter study. Am J Ophthalmol (2003) 1.11
Combined ceftazidime and amikacin resistance among Gram-negative isolates in acute-onset postoperative endophthalmitis: prevalence, antimicrobial susceptibilities, and visual acuity outcome. J Ophthalmic Inflamm Infect (2013) 1.09
Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration. Retina (2009) 1.09
Documentation by spectral domain OCT of spontaneous closure of idiopathic macular holes. Ophthalmic Surg Lasers Imaging (2007) 1.09
Evolving strategies in the management of diabetic macular edema: clinical trials and current management. Can J Ophthalmol (2013) 1.08
Voriconazole and fungal keratitis: a report of two treatment failures. J Ocul Pharmacol Ther (2006) 1.08
Endophthalmitis caused by Moraxella osloensis. Graefes Arch Clin Exp Ophthalmol (2002) 1.08
Ciprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis. Am J Ophthalmol (2004) 1.08
Long-term anatomic and visual acuity outcomes after initial anatomic success with macular hole surgery. Am J Ophthalmol (2003) 1.08
Impact of prior therapy on the recovery and frequency of corneal pathogens. Cornea (2004) 1.07
Management of intraocular foreign bodies: a clinical flight plan. Can J Ophthalmol (2013) 1.06
Re: Bilateral same-day intravitreal injections using a single vial and molecular bacterial screening for safety surveillance. Retina (2013) 1.06
Clinical features and outcomes of pars plana vitrectomy in patients with retained lens fragments. Ophthalmology (2003) 1.06
Primary retinal detachment: scleral buckle or pars plana vitrectomy? Curr Opin Ophthalmol (2006) 1.05
Acute-onset postoperative endophthalmitis: review of incidence and visual outcomes (1995-2001). Ophthalmic Surg Lasers (2002) 1.05
Management of submacular hemorrhage secondary to neovascular age-related macular degeneration with anti-vascular endothelial growth factor monotherapy. Am J Ophthalmol (2013) 1.05
One-year safety and efficacy of intravitreal triamcinolone acetonide for the management of macular edema secondary to central retinal vein occlusion. Retina (2006) 1.05
"Floater scotoma" demonstrated on spectral-domain optical coherence tomography and caused by vitreous opacification. Ophthalmic Surg Lasers Imaging Retina (2013) 1.03
Current Infectious Endophthalmitis Rates After Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents and Outcomes of Treatment. Ophthalmic Surg Lasers Imaging Retina (2015) 1.03
Ocular infections caused by non-tuberculous mycobacteria: update on epidemiology and management. Clin Experiment Ophthalmol (2011) 1.03
Safety and efficacy of intravitreal bevacizumab (avastin) for the management of branch and hemiretinal vein occlusion. Retina (2009) 1.02
Vision loss associated with the use and removal of intraocular silicone oil. Clin Ophthalmol (2008) 1.02